DCK Antibody (C-term)
Purified Rabbit Polyclonal Antibody (Pab)
- SPECIFICATION
- CITATIONS: 3
- PROTOCOLS
- BACKGROUND
Application
| IP, WB, IF, IHC-P, E |
---|---|
Primary Accession | P27707 |
Reactivity | Human, Mouse |
Host | Rabbit |
Clonality | Polyclonal |
Isotype | Rabbit IgG |
Calculated MW | 30519 Da |
Antigen Region | 171-200 aa |
Gene ID | 1633 |
---|---|
Other Names | Deoxycytidine kinase, dCK, DCK |
Target/Specificity | This DCK antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 171-200 amino acids from the C-terminal region of human DCK. |
Dilution | IF~~1:10~50 IP~~1:500~1000 WB~~1:1000 IHC-P~~1:10~50 |
Format | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS. |
Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
Precautions | DCK Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | DCK |
---|---|
Function | Phosphorylates the deoxyribonucleosides deoxycytidine, deoxyguanosine and deoxyadenosine (PubMed:12808445, PubMed:18377927, PubMed:19159229, PubMed:1996353, PubMed:20614893, PubMed:20637175). Has broad substrate specificity, and does not display selectivity based on the chirality of the substrate. It is also an essential enzyme for the phosphorylation of numerous nucleoside analogs widely employed as antiviral and chemotherapeutic agents (PubMed:12808445). |
Cellular Location | Nucleus. |
Provided below are standard protocols that you may find useful for product applications.
Background
Deoxycytidine kinase is responsible for the phosphorylation of several deoxyribonucleosides and their analogs. Deficiency of this enzyme activity is associated with resistance to antiviral and anticancer chemotherapeutic agents, whereas increased enzyme activity is associated with increased activation of these compounds to cytotoxic nucleoside triphosphate derivatives. It is the rate limiting enzyme in the activation of many important anticancer and retroviral drugs and its activity is often decreased in cells that are resistant to cytosine arabinoside.
References
Chottiner, E. G., et al. Proc. Nat. Acad. Sci. 88: 1531-1535 (1991).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.